Arcus Biosciences (RCUS) is up 12.2%, or $2.98 to $27.50.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCUS:
- Merck setback has positives and negatives for Arcus Biosciences, says BofA
- Merck study miss not a read for Arcus, says H.C. Wainwright
- Arcus Biosciences: Buy Rated on Pipeline Control, PD‑1 Backbone Validation, and Upside from Emerging I&I and RCC Programs
- Balanced Risk Profile After TIGIT Failure and Gilead Exit Supports Neutral Stance on Arcus
- Arcus Biosciences discontinues Star-121 study with Gilead due to futility